Lanirapid

Metildigoxin, the active ingredient in Lanirapid, is a cardiac glycoside presented as an oral tablet for prescription use. It is employed to improve cardiac contractility in patients with certain heart rhythm disorders and chronic heart failure. By inhibiting the Na⁺/K⁺‑ATPase pump, it increases intracellular calcium, thereby strengthening myocardial contraction and providing rate control in atrial arrhythmias.

GNH USA supplies Lanirapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and regulatory requirements across the European market.

Metildigoxin acts on the cardiac conduction system and myocardial contractility, making it useful in several cardiovascular conditions.

- Chronic heart failure: improves ventricular contractility and reduces symptoms of fluid overload. - Atrial fibrillation (rate control): slows ventricular response by increasing vagal tone. - Supraventricular tachycardia: assists in rhythm control by enhancing atrioventricular nodal refractory period.

Metildigoxin may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmias (including ventricular tachycardia) - Severe bradycardia - Visual disturbances (yellow‑green halos)

When prescribing Metildigoxin, clinicians should observe several precautionary measures to minimize toxicity.

- Monitor serum electrolytes: especially potassium and magnesium levels should be kept within normal range. - Assess renal function: impaired clearance may require dose adjustment. - Check thyroid status: hypothyroidism can increase drug sensitivity. - Avoid use in patients with second‑degree or higher AV block without a pacemaker. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Metildigoxin interacts with several medicines that can alter its plasma concentration or cardiac effects.

Major Interactions (Avoid): - Amiodarone: markedly increases Metildigoxin serum levels, raising toxicity risk. - Quinidine: potentiates cardiac effects and can precipitate arrhythmias. - Verapamil: enhances drug effect and may lead to severe bradycardia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may cause hypokalemia, increasing toxicity potential. - NSAIDs: can reduce renal clearance and affect drug levels.